Literature DB >> 11102895

Down-regulation of insulin-like growth factor-I receptor and insulin receptor substrate-1 expression in advanced human breast cancer.

B Schnarr1, K Strunz, J Ohsam, A Benner, J Wacker, D Mayer.   

Abstract

The ligands, receptors and related signaling proteins of the insulin-like growth factor family are involved in the regulation of breast-cancer cell growth. We investigated the expression pattern of insulin-like growth factor-I receptor (IGF-IR), insulin receptor (IR) and insulin receptor substrate-1 (IRS-1), a core downstream signaling protein, in 69 primary breast-cancer specimens of different grades and in 21 control tissues by immunohistochemistry. In addition, cell proliferation (percentage of Ki67(+) nuclei) and estrogen receptor (ER) expression were determined. IGF-IR, IRS-1 and IR were expressed mainly in epithelial cells. IRS-1 and IGF-IR were expressed at high levels in control tissues and in well and moderately differentiated carcinomas but at low levels in poorly differentiated breast cancers. IR expression did not show a significant correlation with the differentiation grade of the tissues investigated. Statistical analysis (ROC analysis for tumor grade) demonstrated that down-regulation of IGF-IR and IRS-1 correlated better with tumor progression than reduction of ER expression or increase in cell proliferation, IGF-IR showing the best correlation, followed by IRS-1 and, less significant, ER and Ki67. Our findings clearly show that progression of breast cancer is accompanied by a reduction of IGF-IR/IRS-1 expression and that IGF-IR/IRS-1 expression inversely correlates with high proliferation rate in dedifferentiated breast cancers. The strong correlation of IGF-IR and IRS-1 down-regulation with tumor progression suggests the use of IGF-IR and IRS-1 as a novel set of marker proteins for tumor grading. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11102895     DOI: 10.1002/1097-0215(20001120)89:6<506::aid-ijc7>3.0.co;2-f

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  48 in total

1.  Insulin-like growth factors I and II receptors in the breast cancer survival disparity among African-American women.

Authors:  S Kalla Singh; Q W Tan; C Brito; M De León; D De León
Journal:  Growth Horm IGF Res       Date:  2010-03-27       Impact factor: 2.372

2.  Risk of breast cancer recurrence associated with carbohydrate intake and tissue expression of IGFI receptor.

Authors:  Jennifer A Emond; John P Pierce; Loki Natarajan; Laarni R Gapuz; John Nguyen; Barbara A Parker; Nissi M Varki; Ruth E Patterson
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-04-22       Impact factor: 4.254

3.  Insulin-like growth factor-1 receptor (IGF-1R) expression does not predict for resistance to trastuzumab-based treatment in patients with Her-2/neu overexpressing metastatic breast cancer.

Authors:  Wolfgang J Köstler; Gernot Hudelist; Werner Rabitsch; Klaus Czerwenka; Ruth Müller; Christian F Singer; Christoph C Zielinski
Journal:  J Cancer Res Clin Oncol       Date:  2005-09-24       Impact factor: 4.553

4.  IGF1R Protein Expression Is Not Associated with Differential Benefit to Concurrent Trastuzumab in Early-Stage HER2+ Breast Cancer from the North Central Cancer Treatment Group (Alliance) Adjuvant Trastuzumab Trial N9831.

Authors:  Monica M Reinholz; Beiyun Chen; Amylou C Dueck; Kathleen Tenner; Karla Ballman; Darren Riehle; Robert B Jenkins; Xochiquetzal J Geiger; Ann E McCullough; Edith A Perez
Journal:  Clin Cancer Res       Date:  2017-05-22       Impact factor: 12.531

5.  IGF1R inhibition in mammary epithelia promotes canonical Wnt signaling and Wnt1-driven tumors.

Authors:  Lauren M Rota; Lidia Albanito; Marcus E Shin; Corey L Goyeneche; Sain Shushanov; Emily J Gallagher; Derek LeRoith; Deborah A Lazzarino; Teresa L Wood
Journal:  Cancer Res       Date:  2014-08-04       Impact factor: 12.701

6.  Observations on the effects of Suppressor of Cytokine Signaling 7 (SOCS7) knockdown in breast cancer cells: their in vitro response to Insulin Like Growth Factor I (IGF-I).

Authors:  W Sasi; L Ye; W G Jiang; K Mokbel; A Sharma
Journal:  Clin Transl Oncol       Date:  2013-09-18       Impact factor: 3.405

7.  Insulin-like growth factor-1 receptor is associated with better prognosis in classical Hodgkin's lymphoma: Correlation with MET expression.

Authors:  Young Wha Koh; Dok Hyun Yoon; Cheolwon Suh; Hee Jeong Cha; Jooryung Huh
Journal:  Int J Exp Pathol       Date:  2015-04-27       Impact factor: 1.925

8.  ErbB2 enhances mammary tumorigenesis, oncogene-independent recurrence and metastasis in a model of IGF-IR-mediated mammary tumorigenesis.

Authors:  Craig I Campbell; James J Petrik; Roger A Moorehead
Journal:  Mol Cancer       Date:  2010-09-08       Impact factor: 27.401

9.  Nuclear IRS-1 predicts tamoxifen response in patients with early breast cancer.

Authors:  Ilenia Migliaccio; Meng-Fen Wu; Carolina Gutierrez; Luca Malorni; Syed K Mohsin; D Craig Allred; Susan G Hilsenbeck; C Kent Osborne; Heidi Weiss; Adrian V Lee
Journal:  Breast Cancer Res Treat       Date:  2009-11-19       Impact factor: 4.872

10.  Expression and function of the insulin receptor substrate proteins in cancer.

Authors:  Katerina Mardilovich; Shannon L Pankratz; Leslie M Shaw
Journal:  Cell Commun Signal       Date:  2009-06-17       Impact factor: 5.712

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.